Speaker: 

Jonathan (Ryan) Lozano, PharmD, PGY2 Oncology Resident, Geisinger - has nothing to disclose.

Moderator: 

Tristan Maiers, PharmD, BCOP, PGY2 Residency Program Director, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: - 

- Summarize background on multiple myeloma (MM) and B-cell maturation antigen (BCMA)
- Describe current myeloma treatment guidelines
- Identify agents used to target BCMA in multiple myeloma
- Evaluate the pharmacology of BCMA-targeting drugs, their places in therapy, and best practice for administration

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Tristan Maiers, PharmD, BCOP, Rajiv Panikkar, MD, Michele Long, BSN, Jaime Weeder, NP, Christopher Kashi, PA, and Celeste Vanhorn, CphT have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None

Session date: 
06/17/2025 - 7:00am to 8:00am EDT
Location: 
Virtual via Microsoft Teams
Danville, PA 17822
United States
See map: Google Maps
Add to calendar: 
  • 1.00 AAPA Category I CME
  • 1.00 ACPE
  • 1.00 ACPE Tech
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC
  • 1.00 Participation Credit
Please login or register to take this course.